| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Akebia Therapeutics Inc (NASDAQ: AKBA)
AKBA Technical Analysis
2
| As on 9th Jun 2023 AKBA SHARE Price closed @ 1.26 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.94 & Strong Sell for SHORT-TERM with Stoploss of 2.13 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AKBASHARE Price
| Open | 1.25 | Change | Price | % |
| High | 1.27 | 1 Day | 0.01 | 0.80 |
| Low | 1.21 | 1 Week | 0.13 | 11.50 |
| Close | 1.26 | 1 Month | 0.55 | 77.46 |
| Volume | 961900 | 1 Year | -1.19 | -48.57 |
| 52 Week High 2.93 | 52 Week Low 0.25 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| AKBA Daily Charts |
AKBA Intraday Charts |
Whats New @ Bazaartrend |
AKBA Free Analysis |
|
|
AKBA Important Levels Intraday
| RESISTANCE | 1.38 |
| RESISTANCE | 1.34 |
| RESISTANCE | 1.32 |
| RESISTANCE | 1.29 |
| SUPPORT | 1.23 |
| SUPPORT | 1.20 |
| SUPPORT | 1.18 |
| SUPPORT | 1.14 |
AKBA Forecast April 2024
| 4th UP Forecast | 2.65 |
| 3rd UP Forecast | 2.2 |
| 2nd UP Forecast | 1.93 |
| 1st UP Forecast | 1.65 |
| 1st DOWN Forecast | 0.87 |
| 2nd DOWN Forecast | 0.59 |
| 3rd DOWN Forecast | 0.32 |
| 4th DOWN Forecast | -0.13 |
AKBA Weekly Forecast
| 4th UP Forecast | 1.97 |
| 3rd UP Forecast | 1.74 |
| 2nd UP Forecast | 1.60 |
| 1st UP Forecast | 1.46 |
| 1st DOWN Forecast | 1.06 |
| 2nd DOWN Forecast | 0.92 |
| 3rd DOWN Forecast | 0.78 |
| 4th DOWN Forecast | 0.55 |
AKBA Forecast2024
| 4th UP Forecast | 6.44 |
| 3rd UP Forecast | 4.78 |
| 2nd UP Forecast | 3.75 |
| 1st UP Forecast | 2.73 |
| 1st DOWN Forecast | -0.21 |
| 2nd DOWN Forecast | -1.23 |
| 3rd DOWN Forecast | -2.26 |
| 4th DOWN Forecast | -3.92 |
Akebia Therapeutics Inc ( NASDAQ USA Symbol : AKBA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AKBA Business Profile
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 245 First Street, Cambridge, MA, United States, 02142
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service